Abstract:BackgroundTo evaluate the safety and efficacy of hybutimibe plus atorvastatin for lipid control in hypercholesterolemia patients with atherosclerotic cardiovascular disease risk equivalent.MethodsIn this double-blind phase III study, we 1:1 randomly assigned 255 hypercholesterolemia patients with atherosclerotic cardiovascular disease to receive hybutimibe plus atorvastatin or placebo plus atorvastatin. The primary endpoint was the rate of change of plasma low-density lipoprotein-cholesterol (LDL-C) level at 12 weeks from baseline. The secondary endpoints were plasma total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), non-HDL-C, apoprotein (Apo) B, and 2-, 4-, 8-, and 12-week Apo A1 levels change rate and rates of change of plasma LDL-C levels at 2, 4, and 8 weeks from baseline.ResultsFrom April 2016 to January 2018, 128 in the hybutimibe plus atorvastatin group and 125 in the atorvastatin group were included in modified intention-to-treat (mITT) analysis. After 12 weeks of treatment, LDL-C level changed from 2.61 mmol/L (±0.30) at baseline to 2.18 mmol/L (±0.45) in the hybutimibe plus atorvastatin group and from 2.58 (±0.31) mmol/L to 2.40 (± 0.46) mmol/L in the atorvastatin group (P < 0.0001), in mITT. The change rate in the hybutimibe plus atorvastatin group was significantly higher than that in the atorvastatin group (P < 0.0001); the estimated mean rates of change were −16.39 (95% confidence interval: −19.04, −13.74) and −6.75 (−9.48, −4.02), respectively. Consistently, in per-protocol set (PPS) analysis, the rate of change of LDL-C in the hybutimibe plus atorvastatin group was significantly higher than that in atorvastatin group. Significant decreases in the change rates of non-HDL-C, TC, and Apo B at 2, 4, 8, and 12 weeks (all P < 0.05) were observed for hybutimibe plus atorvastatin, while the differences were not significant for HDL-C, TG, and Apo-A1 (all P > 0.05). During the study period, no additional side effects were reported.ConclusionsHybutimibe combined with atorvastatin resulted in significant improvements in LDL-C, non-HDL-C, TC, and Apo B compared with atorvastatin alone. The safety and tolerability were also acceptable, although additional benefits of hybutimibe plus atorvastatin were not observed compared with atorvastatin alone in HDL-C, TG, and Apo-A1.

A clinical trial for evaluating efficacy and safety of amlodipine besylate/atorvastatin calcium in treating hypertension complicated with hyperlipidemia

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

Efficacy and Safety of Fixed Compound Amlodipine and Atorvastatin in Patients with Hypertension Accompanying Hyperlipidemia

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Efficacy and Safety of Hybutimibe in Combination with Atorvastatin for Treatment of Hypercholesteremia among Patients with Atherosclerotic Cardiovascular Disease Risk Equivalent: A Multicenter, Randomized, Double-Blinded Phase III Study.

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment

The Effectiveness and Safety of L-amlodipine Besylate for Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension

Combination Of Amlodipine With Diuretics Or Telmisartan In High-Risk Hypertensive Patients: The Chinese Hypertension Intervention Efficacy Study (Chief)

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

The Efficacy and Safety of Amlodipine Maleate on Patients with Mild to Moderate Essential Hypertension

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Randomized, double-blind, parallel controlled,multicentre clinical trial of fixed combination of nitrendipine and atenolol in the treatment of mild to moderate essential hypertension

Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial

Amlodipine/valsartan 5/160mg Versus Valsartan 160mg in Chinese Hypertensives

Effect of nifedipine controlled released tablet and atorvastatin on carotid intimamedia thickness and vascular endothelial function in patients with hypertension

Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial

[Efficacy and Safety of Combination Therapy with Simvastatin and Fenofibrate for Combined Hyperlipidemia].

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension